SCHEMBL2863274

SCHEMBL2863274

O=C(Nc1cccc(F)c1)C1CNCC2C(=O)OC(c3ccccc3)(c3ccccc3)N12

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.41
POLB P06746 2/20 0.41
HTT P42858 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
NPSR1 Q6W5P4 2/20 0.40
MEN1 O00255 3/20 0.39
KMT2A Q03164 3/20 0.39
USP2 O75604 3/20 0.39
GAA P10253 1/20 0.39
MAPT P10636 1/20 0.39
MAPK1 P28482 1/20 0.39
NPC1 O15118 2/20 0.39
HPGD P15428 2/20 0.39
RAB9A P51151 1/20 0.39
CYP2D6 P10635 2/20 0.39
KDM4E B2RXH2 1/20 0.39
GLA P06280 1/20 0.39
ALOX15 P16050 1/20 0.39
TSHR P16473 1/20 0.38
CYP2C19 P33261 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2856717 0.89 NPSR1 (0.46) POLBNPSR1MEN1KMT2AMAPT
SCHEMBL2864543 0.88 POLB (0.38) POLBNPSR1MEN1KMT2ANPC1
SCHEMBL2861757 0.85 NPSR1 (0.47) ALDH1A1NPSR1KMT2AKDM4EL3MBTL1
SCHEMBL2860452 0.85 GRIN2B (0.43) ALDH1A1HTTNPSR1MAPTNPC1
SCHEMBL2864826 0.84 F10 (0.40) ALDH1A1POLBHTTTDP1NPSR1
SCHEMBL2861932 0.84 ALDH1A1 (0.39) ALDH1A1HTTTDP1NPSR1MEN1
SCHEMBL2870723 0.84 MEN1 (0.39) TDP1NPSR1MEN1KMT2AMAPT
SCHEMBL2865017 0.83 GRIN2B (0.42) ALDH1A1MEN1KMT2ANPC1HPGD
SCHEMBL2863506 0.83 RXFP2 (0.39) NPSR1MAPTNPC1RAB9A
SCHEMBL2861976 0.83 ALDH1A1 (0.40) ALDH1A1POLBHTTTDP1NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7795267-B2 Bicyclic piperazine compound having TGR23 antagonistic activity TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-09-14 US disclosed
US-20070072865-A1 Bicyclic piperazine compound and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-03-29 US disclosed
EP-1661898-A1 BICYCLIC PIPERAZINE COMPOUND AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2006-05-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070072865-A1 Bicyclic piperazine compound and use thereof GPR3, FFAR3, LPAR3 ALDH1A1 2926/4885POLB 3625/4885HTT 3138/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.